Which Pre-Transplant chemo works best for MDS/AML? new trial aims to find out
NCT ID NCT04994808
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests two different chemotherapy combinations (treosulfan-based vs. clofarabine-based) given before a donor stem cell transplant in adults with myelodysplastic syndromes or acute myeloid leukemia. The goal is to see which regimen leads to better relapse-free survival. The study enrolled 23 participants and is no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Treosulfan, Clofarabine, Fludarabine, Total-Body Irradiation
What this could lead to
If successful, this study could show which chemotherapy regimen before a stem cell transplant works better to keep MDS or AML from coming back.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. Both regimens have risks like infection, graft-versus-host disease, and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States